Zacks Investment Research upgraded shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) from a hold rating to a buy rating in a research note released on Wednesday. Zacks Investment Research currently has $4.00 price target on the biopharmaceutical company’s stock.

According to Zacks, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. “

Several other brokerages also recently weighed in on GLMD. Maxim Group reissued a buy rating and issued a $9.00 target price (down previously from $24.00) on shares of Galmed Pharmaceuticals in a research note on Monday, August 1st. FBR & Co set a $20.00 target price on shares of Galmed Pharmaceuticals and gave the company a buy rating in a research note on Friday, August 5th. Finally, HC Wainwright reissued a buy rating on shares of Galmed Pharmaceuticals in a research note on Monday, November 7th. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and an average price target of $12.20.

Galmed Pharmaceuticals (NASDAQ:GLMD) opened at 3.63 on Wednesday. The stock’s market capitalization is $44.10 million. The company’s 50-day moving average is $3.73 and its 200-day moving average is $4.20. Galmed Pharmaceuticals has a 12 month low of $2.78 and a 12 month high of $9.70.

Galmed Pharmaceuticals (NASDAQ:GLMD) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.05. Equities research analysts forecast that Galmed Pharmaceuticals will post ($1.39) EPS for the current year.

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. P.A.W. Capital Corp acquired a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the third quarter, according to its most recent filing with the SEC. The fund acquired 60,000 shares of the biopharmaceutical company’s stock, valued at approximately $266,000. P.A.W. Capital Corp owned approximately 0.54% of Galmed Pharmaceuticals as of its most recent SEC filing. 5.05% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Galmed Pharmaceuticals Ltd. (GLMD) Upgraded to “Buy” at Zacks Investment Research” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2016/11/24/galmed-pharmaceuticals-ltd-glmd-upgraded-to-buy-at-zacks-investment-research.html.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

5 Day Chart for NASDAQ:GLMD

Receive News & Stock Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related stocks with our FREE daily email newsletter.